Found: 23
Select item for more details and to access through your institution.
Big opportunities for small molecules in immuno-oncology.
- Published in:
- Nature Reviews Drug Discovery, 2015, v. 14, n. 9, p. 603, doi. 10.1038/nrd4596
- By:
- Publication type:
- Article
Hürthle cell carcinoma: A 60-year experience.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2002, v. 9, n. 2, p. 197, doi. 10.1007/BF02557374
- By:
- Publication type:
- Article
Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer.
- Published in:
- International Journal of Cancer, 1998, v. 79, n. 1, p. 8, doi. 10.1002/(SICI)1097-0215(19980220)79:1<8::AID-IJC2>3.0.CO;2-5
- By:
- Publication type:
- Article
The regulatory landscape for actively personalized cancer immunotherapies.
- Published in:
- Nature Biotechnology, 2013, v. 31, n. 10, p. 880, doi. 10.1038/nbt.2708
- By:
- Publication type:
- Article
A methodological framework to enhance the clinical success of cancer immunotherapy.
- Published in:
- 2011
- By:
- Publication type:
- Letter
Desmoid tumors of the head and neck-A clinical study of a rare entity.
- Published in:
- Head & Neck, 2000, v. 22, n. 8, p. 814, doi. 10.1002/1097-0347(200012)22:8<814::AID-HED11>3.0.CO;2-#
- By:
- Publication type:
- Article
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
- Published in:
- Annals of the New York Academy of Sciences, 2013, v. 1291, n. 1, p. 1, doi. 10.1111/nyas.12180
- By:
- Publication type:
- Article
Adrenocortical Adenoma and Carcinoma: Histopathological and Molecular Comparative Analysis.
- Published in:
- Modern Pathology, 2003, v. 16, n. 8, p. 742, doi. 10.1097/01.MP.0000081730.72305.81
- By:
- Publication type:
- Article
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium.
- Published in:
- Cancer Immunology, Immunotherapy, 2009, v. 58, n. 10, p. 1701, doi. 10.1007/s00262-009-0681-z
- By:
- Publication type:
- Article
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI).
- Published in:
- Cancer Immunology, Immunotherapy, 2008, v. 57, n. 3, p. 303, doi. 10.1007/s00262-007-0380-6
- By:
- Publication type:
- Article
High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas.
- Published in:
- 2001
- By:
- Publication type:
- journal article
Clinicopathologic analysis of patients with adult rhabdomyosarcoma.
- Published in:
- Cancer (0008543X), 2001, v. 91, n. 4, p. 794, doi. 10.1002/1097-0142(20010215)91:4<794::AID-CNCR1066>3.0.CO;2-Q
- By:
- Publication type:
- Article
A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2006, v. 58, n. 6, p. 759, doi. 10.1007/s00280-006-0235-4
- By:
- Publication type:
- Article
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 10, p. 1, doi. 10.1038/s41408-020-00369-0
- By:
- Publication type:
- Article
Harmonization of Immune Biomarker Assays for Clinical Studies.
- Published in:
- Science Translational Medicine, 2011, v. 3, n. 108, p. 1, doi. 10.1126/scitranslmed.3002785
- By:
- Publication type:
- Article
A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols.
- Published in:
- 2011
- By:
- Publication type:
- journal article
A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols.
- Published in:
- Journal of Translational Medicine, 2011, v. 9, n. 1, p. 108, doi. 10.1186/1479-5876-9-108
- By:
- Publication type:
- Article
Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment.
- Published in:
- Health & Quality of Life Outcomes, 2012, v. 10, n. 1, p. 66, doi. 10.1186/1477-7525-10-66
- By:
- Publication type:
- Article
Giant cellular blue nevus of the anterior chest wall mimicking metastatic melanoma to the breast: A case report.
- Published in:
- Journal of Surgical Oncology, 2000, v. 74, n. 4, p. 278, doi. 10.1002/1096-9098(200008)74:4<278::AID-JSO7>3.0.CO;2-D
- By:
- Publication type:
- Article
Guidelines for the automated evaluation of Elispot assays
- Published in:
- Nature Protocols, 2015, v. 10, n. 7, p. 1098, doi. 10.1038/nprot.2015.068
- By:
- Publication type:
- Article
Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.
- Published in:
- Pigment Cell & Melanoma Research, 2015, v. 28, n. 5, p. 611, doi. 10.1111/pcmr.12383
- By:
- Publication type:
- Article
Improved Endpoints for Cancer Immunotherapy Trials.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2010, v. 102, n. 18, p. 1388, doi. 10.1093/jnci/djq310
- By:
- Publication type:
- Article
Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy.
- Published in:
- 2011
- By:
- Publication type:
- journal article